ARGENX Achieves First Operating Profitability with $1.1B in 2025, Reports $4.2B Sales & Positive Phase 3 VYVGART Data in Ocular MG

summarizeSummary

ARGENX SE reported its first year of operating profitability in 2025 with $1.1 billion in operating income and $4.2 billion in global product net sales, alongside positive Phase 3 results for VYVGART in ocular myasthenia gravis, supporting a planned label expansion.

check_boxKey Events

• Achieved First Year of Operating Profitability

  ARGENX SE reported $1.1 billion in operating income for the full year 2025, marking its first year of operating profitability, a significant improvement from an operating loss in 2024.

• Strong Full-Year 2025 Sales Growth

  Global product net sales for VYVGART reached $4.2 billion in 2025, representing a 90% year-over-year increase, with Q4 2025 sales at $1.3 billion, up 74% from Q4 2024.

• Positive Phase 3 Results for VYVGART in Ocular MG

  The Phase 3 ADAPT OCULUS study for VYVGART SC in ocular myasthenia gravis (oMG) met its primary endpoint (p=0.012), demonstrating statistically significant improvement and supporting a planned sBLA submission.

• Key Regulatory Milestone Approaching

  The PDUFA target action date for VYVGART's label expansion into anti-AChR antibody-negative (seronegative) generalized myasthenia gravis is set for May 10, 2026.

auto_awesomeAnalysis

ARGENX SE delivered a strong performance in 2025, achieving its first year of operating profitability with $1.1 billion in operating income, a significant turnaround from a loss in the prior year. This financial milestone is underpinned by robust global product net sales of $4.2 billion for VYVGART, representing an impressive 90% year-over-year growth. Concurrently, the company announced positive Phase 3 results for VYVGART SC in ocular myasthenia gravis (oMG), meeting its primary endpoint and paving the way for a planned supplemental Biologics License Application (sBLA). This clinical success, combined with an upcoming PDUFA date for seronegative generalized myasthenia gravis, reinforces VYVGART's market leadership and expands its addressable patient population. The company's strategic 'Vision 2030' and a robust pipeline with multiple programs advancing into later stages of development signal continued growth potential, despite the discontinuation of the adimanebart ALS program. This comprehensive update provides a highly positive outlook for ARGENX SE, demonstrating strong execution across both commercial and clinical fronts.